| Filed On | Filing |
|---|---|
| 12 Dec 2022 |
8-K/A: Financial Statements and Exhibits
Effective October 20, 2022, Sunshine Biopharma, Inc. (“Sunshine” or the “Company”) entered into a Share Purchase Agreement with Nora Pharma Inc. (the “Nora Purchase Agreement”), wherein the Company acquired all of the issued and outstand... |
| 09 Aug 2016 |
8-K/A: Unregistered Sales of Equity Securities
As previously reported, on October 8, 2015, we acquired U.S. Patent Number 8,236,935 (the “Patent”) for the anticancer compound, Adva-27a, which includes all rights to this intellectual property within the United States in exchange for a... |
| 07 Feb 2012 |
8-K/A: Changes in Registrant's Certifying Accountant
On January 30, 2012 my appointment as auditor for Sunshine Biopharma, Inc. ceased. I have read Sunshine Biopharma, Inc.’s statements included under Item 4.01 of its Form 8-K/A dated February 6, 2012 and agree with such statements, insofa... |
| 19 Jan 2010 |
8-K/A: Completion of Acquisition or Disposition of Assets; Unregistered Sales of Equity Securities +2 more
THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made this 20th day of August, 2009, by and between Advanomics Corporation, a Canadian corporation (the “Licensor”), with its principal place of business at 6100 Royalmount Avenue, Mon... |
Loading...